{"product_id":"coherus-five-forces-analysis","title":"Coherus Biosciences Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCoherus Biosciences operates in a dynamic biopharmaceutical landscape, facing distinct pressures from buyer power, the threat of new entrants, and the intensity of rivalry. Understanding these forces is crucial for navigating its competitive environment.\u003c\/p\u003e\n\u003cp\u003eThe complete report reveals the real forces shaping Coherus Biosciences’s industry—from supplier influence to threat of new entrants. Gain actionable insights to drive smarter decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Raw Material Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe biopharmaceutical sector, which includes companies like Coherus Biosciences, often faces a situation where only a few specialized suppliers provide essential raw materials, cell lines, and crucial reagents. This concentration means these suppliers can wield significant influence.\u003c\/p\u003e\n\u003cp\u003eWhen these suppliers are few in number or possess unique, proprietary inputs, their bargaining power escalates. This can translate into increased costs for Coherus or create potential weaknesses in its supply chain, making it harder to secure necessary components. For instance, in 2024, ongoing supply chain disruptions across various industries, including biopharma, have been widely reported, further strengthening the negotiating position of many suppliers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Manufacturing and Contract Development and Manufacturing Organizations (CDMOs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiosimilar manufacturing is a complex process, often relying on specialized Contract Development and Manufacturing Organizations (CDMOs).  The scarcity of CDMOs with the necessary expertise and capacity for large-scale biologic production grants them considerable leverage. This directly influences Coherus Biosciences' production costs and development timelines.\u003c\/p\u003e\n\u003cp\u003eA concentrated CDMO market poses a significant risk. For instance, disruptions at a key manufacturing facility in 2023 affected numerous biopharmaceutical companies, underscoring the dependency on a limited number of specialized providers and highlighting the bargaining power these CDMOs wield.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Technology and Equipment Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers of advanced bioprocessing equipment, analytical instruments, and proprietary drug delivery systems wield significant influence. Coherus's dependence on these specialized technologies, crucial for producing biosimil products like the UDENYCA ONBODY™ Injector, allows these providers to set terms and pricing, impacting Coherus's cost structure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Service Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCoherus Biosciences' increasing emphasis on innovative oncology and pipeline expansion means a greater dependence on specialized Research and Development (R\u0026amp;D) service providers, particularly Contract Research Organizations (CROs). These CROs possess critical expertise and infrastructure for conducting complex clinical trials, especially for novel oncology candidates like casdozokitug and CHS-114.  The specialized nature of these services grants CROs considerable bargaining power, as finding alternative providers with equivalent capabilities can be challenging and time-consuming.\u003c\/p\u003e\n\u003cp\u003eThe bargaining power of R\u0026amp;D service providers, such as CROs, is amplified by the specialized knowledge and advanced facilities they offer. For Coherus, particularly as it navigates the intricate landscape of oncology drug development, the ability of CROs to manage sophisticated trials is paramount. This reliance means CROs can command higher prices and favorable terms. For instance, the global CRO market was valued at approximately $45.4 billion in 2023 and is projected to grow significantly, indicating strong demand and a robust market for these specialized services.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecialized Expertise:\u003c\/strong\u003e CROs offer niche skills in areas like oncology trial design and execution, which are difficult for biopharma companies to replicate internally.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInfrastructure Requirements:\u003c\/strong\u003e The capital investment in advanced clinical trial infrastructure and regulatory compliance is substantial, favoring established CROs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePipeline Focus:\u003c\/strong\u003e As Coherus advances novel candidates like casdozokitug, the need for CROs with proven track records in similar therapeutic areas increases their leverage.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Growth:\u003c\/strong\u003e The expanding global CRO market, projected to reach over $70 billion by 2028, reflects the high demand and value placed on these outsourced R\u0026amp;D capabilities.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Holders for Manufacturing Processes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntellectual property holders for manufacturing processes can significantly influence Coherus Biosciences. While Coherus focuses on biosimilars to already off-patent drugs, the actual methods used to produce these complex biological products can involve proprietary technologies or patented steps. Suppliers who own these crucial intellectual properties, whether for specific bioprocessing techniques or formulation methods, can wield considerable power. This leverage might translate into higher licensing fees or restrictions on Coherus’s ability to source from alternative suppliers, directly impacting the cost and complexity of bringing their biosimilar products to market. For example, specialized cell line development or purification technologies might be patented, creating a dependency for biosimilar manufacturers.\u003c\/p\u003e\n\u003cp\u003eThe bargaining power of suppliers in this context is amplified by the specialized nature of biopharmaceutical manufacturing. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eProprietary Technologies:\u003c\/strong\u003e Suppliers may hold patents on unique cell culture media, bioreactor designs, or downstream purification processes essential for biosimilar production.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLicensing Fees:\u003c\/strong\u003e The cost of licensing these patented technologies can be a significant factor in the overall cost of goods sold for Coherus.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLimited Alternatives:\u003c\/strong\u003e If only a few suppliers possess the necessary intellectual property, Coherus faces fewer options, increasing supplier leverage.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegulatory Hurdles:\u003c\/strong\u003e Even if a process is conceptually similar, the specific patented or proprietary steps may require extensive validation and regulatory approval, further entrenching the supplier's position.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Suppliers: Biopharma's Powerful Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe bargaining power of suppliers for Coherus Biosciences is significant due to the specialized nature of biopharmaceutical inputs and services. This includes raw materials, cell lines, reagents, Contract Development and Manufacturing Organizations (CDMOs), and Contract Research Organizations (CROs).  The concentration of expertise and proprietary technologies among these suppliers allows them to command higher prices and favorable terms.\u003c\/p\u003e\n\u003cp\u003eFor instance, the global Contract Research Organization (CRO) market was valued at approximately $45.4 billion in 2023, highlighting the substantial demand and reliance on these specialized R\u0026amp;D service providers.  This strong market position grants CROs considerable leverage, especially when Coherus is developing complex oncology candidates.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eSupplier Type\u003c\/th\u003e\n\u003cth\u003eKey Inputs\/Services\u003c\/th\u003e\n\u003cth\u003eImpact on Coherus\u003c\/th\u003e\n\u003cth\u003eSupplier Leverage Factors\u003c\/th\u003e\n\u003cth\u003e2023\/2024 Data Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialized Reagents \u0026amp; Cell Lines\u003c\/td\u003e\n\u003ctd\u003eBioprocessing inputs\u003c\/td\u003e\n\u003ctd\u003eIncreased raw material costs, potential supply disruptions\u003c\/td\u003e\n\u003ctd\u003eFew specialized providers, proprietary inputs\u003c\/td\u003e\n\u003ctd\u003eOngoing supply chain disruptions reported across biopharma in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMOs\u003c\/td\u003e\n\u003ctd\u003eLarge-scale biologic production\u003c\/td\u003e\n\u003ctd\u003eHigher manufacturing costs, extended development timelines\u003c\/td\u003e\n\u003ctd\u003eScarcity of experienced CDMOs for biologics\u003c\/td\u003e\n\u003ctd\u003eDisruptions at key CDMO facilities impacted multiple biopharma companies in 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\u003c\/td\u003e\n\u003ctd\u003eClinical trial management (e.g., oncology)\u003c\/td\u003e\n\u003ctd\u003eHigher R\u0026amp;D service costs, reliance on specialized expertise\u003c\/td\u003e\n\u003ctd\u003eNiche skills, advanced infrastructure, growing market\u003c\/td\u003e\n\u003ctd\u003eGlobal CRO market valued at ~$45.4 billion in 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThis analysis tailors Porter's Five Forces to Coherus Biosciences, examining the intensity of rivalry, buyer and supplier power, threat of new entrants, and the impact of substitutes on its biosimilar market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCoherus Biosciences' Porter's Five Forces analysis simplifies complex competitive dynamics, offering a clear, actionable framework to identify and mitigate threats, thereby relieving strategic planning pain points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Systems and Pharmacy Benefit Managers (PBMs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHealthcare systems and Pharmacy Benefit Managers (PBMs) wield considerable bargaining power when procuring biosimilars. Their substantial purchasing volumes and influence over drug formularies give them leverage to negotiate lower prices.  For instance, in 2024, PBMs continued to drive down biosimilar costs through strategies like private label programs and direct negotiations, impacting Coherus Biosciences' pricing power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice Sensitivity and Cost-Effectiveness Demands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe core value of biosimilars lies in providing effective treatments at a lower cost, making patients and payers keenly focused on price. This price sensitivity is amplified by the escalating costs of traditional biologic drugs, driving a strong demand for more economical alternatives.\u003c\/p\u003e\n\u003cp\u003eIn 2024, the U.S. biosimilars market is projected to reach approximately $100 billion, with a significant portion of this growth fueled by the demand for cost savings. Customers, including large payers and healthcare systems, leverage this demand to negotiate aggressively for lower prices from biosimilar manufacturers like Coherus Biosciences.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvailability of Multiple Biosimilar Competitors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe increasing number of biosimilar competitors directly amplifies customer bargaining power. When multiple biosimilars are available for a reference biologic, patients and payers have more choices, which naturally drives down prices and gives them greater negotiating leverage against manufacturers like Coherus Biosciences.\u003c\/p\u003e\n\u003cp\u003eThe biosimilar landscape has significantly expanded, with the FDA approving a growing number of these complex generics. In fact, the number of FDA-approved biosimilar products has doubled since 2020, creating a more competitive environment where customers can demand lower prices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Policy Support for Biosimilar Uptake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGovernment policies and regulatory shifts are actively bolstering biosimilar adoption, directly enhancing customer bargaining power. Agencies like the FDA and CMS are introducing incentives that encourage the use of these more affordable alternatives.\u003c\/p\u003e\n\u003cp\u003eThe FDA's approval of 19 biosimilars in 2024, a record high, signifies a strong regulatory push. This increased availability and official endorsement empower customers to demand lower prices and greater access to biosimilar options.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eGovernment Support:\u003c\/strong\u003e Policies from FDA and CMS increasingly favor biosimilar uptake.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCustomer Empowerment:\u003c\/strong\u003e Incentives like pass-through payments and biosimilar-first mandates strengthen customer leverage.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Growth:\u003c\/strong\u003e The 19 biosimilar approvals in 2024 highlight a supportive regulatory environment for customers.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSwitching Costs for Customers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eWhile physician comfort with existing treatments can create some inertia, the actual switching costs for healthcare providers and patients to adopt biosimilars are typically quite low, especially when interchangeability designations are in place. This ease of transition empowers customers, allowing them to readily choose the most cost-effective biosimilar option. For instance, the European Medicines Agency (EMA) affirmed the interchangeability of biosimilars in 2022, and the U.S. Food and Drug Administration (FDA) has been moving towards similar guidance, further reducing perceived barriers to adoption.\u003c\/p\u003e\n\u003cp\u003eThe decreasing switching costs directly impact the bargaining power of customers in the biosimilar market. As it becomes easier and less costly to switch from a reference biologic to a biosimilar, or between different biosimilars, customers gain more leverage. This can lead to increased price competition among biosimilar manufacturers, as providers and patients can more readily seek out the best value. For example, in 2023, the U.S. market saw several biosimilars for adalimumab (Humira) launch, intensifying competition and potentially driving down prices for patients and payers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eLower Switching Costs:\u003c\/strong\u003e Healthcare providers and patients face minimal costs when switching to biosimilars compared to novel therapies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInterchangeability Designation:\u003c\/strong\u003e Approvals like the EMA's 2022 ruling and ongoing FDA considerations for interchangeability reduce barriers to switching.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePrice Sensitivity:\u003c\/strong\u003e The ease of switching encourages customers to prioritize cost-effectiveness, increasing their bargaining power.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Competition:\u003c\/strong\u003e The introduction of multiple biosimilars for a single reference biologic, as seen with adalimumab in 2023, amplifies this effect.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCustomer Leverage Reshapes Biosimilar Pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCustomers, particularly large healthcare systems and Pharmacy Benefit Managers (PBMs), hold significant sway in the biosimilar market due to their substantial purchasing volumes and influence over drug formularies.  This leverage allows them to negotiate aggressively for lower prices, a trend that intensified in 2024 as PBMs implemented strategies like private label programs. The market's growing demand for cost savings, projected to reach approximately $100 billion in the U.S. by 2024, further empowers these customers to drive down prices from manufacturers like Coherus Biosciences.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFactor\u003c\/td\u003e\n\u003ctd\u003eDescription\u003c\/td\u003e\n\u003ctd\u003eImpact on Coherus Biosciences\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePurchasing Volume\u003c\/td\u003e\n\u003ctd\u003eLarge payers and healthcare systems buy in bulk.\u003c\/td\u003e\n\u003ctd\u003eIncreases their negotiating power for lower prices.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormulary Influence\u003c\/td\u003e\n\u003ctd\u003ePBMs control which drugs are covered and preferred.\u003c\/td\u003e\n\u003ctd\u003eAllows them to dictate terms and favor lower-cost biosimilars.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice Sensitivity\u003c\/td\u003e\n\u003ctd\u003eHigh demand for cost-effective alternatives to expensive biologics.\u003c\/td\u003e\n\u003ctd\u003eManufacturers face pressure to offer competitive pricing.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNumber of Competitors\u003c\/td\u003e\n\u003ctd\u003eIncreasing number of biosimilar approvals.\u003c\/td\u003e\n\u003ctd\u003eAmplifies customer choice and bargaining leverage.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eCoherus Biosciences Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact document you'll receive immediately after purchase—no surprises, no placeholders. The comprehensive Coherus Biosciences Porter's Five Forces Analysis details the bargaining power of buyers and suppliers within the biosimilar market, alongside the threat of new entrants and the intensity of rivalry among existing competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55676012790137,"sku":"coherus-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/coherus-five-forces-analysis.png?v=1755813026","url":"https:\/\/portersfiveforce.com\/products\/coherus-five-forces-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}